The significance of neuron-specific enolase (NSE) in the diagnosis and treatment monitoring of lung cancer was investigated in comparison with such established tumour markers as carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), ferritin and calcitonin. We determined the serum concentrations of these tumour markers in 25 patients with small cell lung cancer (SCLC), 30 patients with non small cell lung cancer (NSCLC), and 38 patients with benign pulmonary diseases (BPD). In 14 patients with lung cancer, it was possible to follow up the behaviour of the tumour markers under treatment for up to 16 months. Calcitonin proved to have a surprisingly low sensitivity for SCLC. The utility of TPA and of ferritin was restricted, although the sensitivity was comparably high, by the high rate of false positive results. For NSCLC, CEA proved to be the best tumour marker. At present, NSE appears to be the tumour marker with the greatest specificity and sensitivity for SCLC. Its determination in the diagnosis, treatment and follow-up of SCLC makes good sense.
LloydR.V., SissonJ.C., MarangosP.J.Calcitonin, carcinoembryonic antigen and neuron-specific enolase in medullary thyroid carcinoma.Cancer1983; 51: 2234–9.
2.
OdelstadL., PahlmanS., LackgrenG., LarssonE., GrotteG., NilssonK.Neuron specific enolase: A marker for differential diagnosis of neuroblastoma and wilms's tumor.J Ped Surg1982; 17: 381–5.
3.
SheppardM.N., CorrinB., BennettM.H., MarangosP.J., BloomS.R., PolakJ.M.Immunocytochemical localization of neuron specific enolase in small cell carcinomas and carcinoid tumours of the lung.Histopathology1984; 8: 171–81.
4.
SpringallD.R., LackieP., LeveneM.M., MarangosP.J., PolakJ.M.Immunostaining of neuron-specific enolase is a valuable aid to the cytological diagnosis of neuroendocrine tumours of the lung.Pathology1984; 143: 259–70.
5.
TsokosM., LinnoilaR.I., ChandraR.S., TricheT.J.Neuron-specific enolase in the diagnosis of neuroblastoma and other small, round-cell tumors in children.Hum Pathol1984; 15: 575–84.
6.
VinoresS.A., BonninJ.M., RubinsteinL.J., MarangosP.J.Immunohistochemical demonstration of neuron-specific enolase in neoplasm of the CNS and other tissues.Arch Pathol Lab Med1984; 108: 536–40.
7.
AkounG.M., ScarnaH.M., MilleronB.J., BenichouM.P., HermanD.P.Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer.Chest1985; 87: 39–43.
8.
AriyoshiY., KatoK., IshiguroY., OtaK., SatoT., SuchiT.Evaluation of serum neuron-specific enolase as a tumor marker for carcinoma of the lung.Gann1983; 74: 219–25.
9.
CarneyD.N., IhdeD.C., CohenM.H.. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer.Lancet1982; 1: 583–5.
10.
CooperE.H., SplinterT.A.W., BrownD.A., MuersM.F., PeakeM.D., PearsonS.L.Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer.Br J Cancer1985; 52: 333–8.
11.
FischbachW., JanyB., NelkenstockR.Bedeutung der Neuron-Spezifischen Enolase (NSE) in der Diagnostik von Bronchialkarzinomen und neuroendokrinen Tumoren.Dtsch med Wschr1986; 111: 1721–5.
12.
JohnsonD.H., MarangosP.J., ForbesJ.T.. Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung.Cancer Res1984; 44: 5409–14.
13.
ScarnaH., AkounG., BenichouM., MilleronB.Serum neuron-specific enolase levels in lung diseases; a valuable marker for small-cell lung cancer.Prot Biol Fluids1984; 643–6.
14.
WildeJ., MatthäiC.H.Eine epidemiologische Studie zur Situation der Erfassung und Therapie Lugenkrebskran-ker im Erfurt. In: TrendelenburgF. (ed) Tumoren der Atmungsorgane und des Mediastinums B.Springer, 1985; 178–80.
DringsP., MankeH.G., HolleH., VictorN., HavemannK.. The tumour markers CEA, calcitonin and ACTH in a prospective trial of small cell lung cancer (SCLC).Proc 13th Int Congr Chemotherapy1983; 274: 45–8.
17.
GroppC., HavemannK., LusterW., LehmannF.G.Carcinoembryonic antigen as a parameter for staging and monitoring of therapy in patients with lung cancer. In: UhlenbruckG., WintzerG., Hrsg. CEA and andere Tumormarker.Leonberg: Tumor Diagnostik, 1981; 198–209.
18.
KrischkeW., NiederleN., ScütteJ., PfeifferR., SeeberS., SchmidtC.G.Serial serum determinations of carcinoembryonic antigen (CEA) in small lung cancer (SCLC): Is there any clinical relevance? Verh Dtsch Krebs Ges, Stuttgart: G.Fischer,1984; 5: 367–70.
19.
VincentR.G., ChuTm, FergenT.B., OstranderM.Carcinoembryonic antigen in 228 patients with carcinoma of the lung.Cancer1975; 36: 2069–76.
20.
WaalkesT.P., AbeloffM.D., WooK.B., EttingerD.S., Rud-donR.W., AldenderferP.Carcinoembryonic antigen for monitoring patients with small cell carcinoam on the lung during treatment.Cancer Res1980; 40: 4420–7.
21.
LüthgensM., SchlegelG.Sensitivity and specifity of TPA, CEA and the index of both markers in various malignancies. In: Peeter H (ed) Proteides Biol Fluids.Oxford: Pergamon Press, Collog.1984; 31: 475–8.
22.
LüthgensM., SchlegelG.Verlaufskontrolle bei Bronchialkarzinomen mit Tissue polypeptide Antigen und carcinoembryonalem Antigen.Tumor Diagnostik & Therapie1985; 6: 1–7.
23.
GroppC., HavemannK., SchauerA.Ectopic hormones in lung cancer patients at diagnosis and during therapy.Cancer1980; 46: 347–54.
24.
MulderH., HackengW.H.L., SilberbuschJ., den OttolanderG.J.H., van der MeerC.Value of serum calcitonin estimation in clinical oncology.Br J Cancer1981; 43: 786–92.
25.
WinkelmannW., DeußU., AllolioB.. Adrenocorti-cotropin, calcitonin, and antidiuretic hormone as tumor markers in patients with bronchogenic carcinoma of various histological types.Klin Wochenschr1984; 62: 1018–24.
